Payment overview · 2025
General Payments
$119.06
6 reported records · 3 companies
Healthcare provider profile · identity verified
Robert E Walton, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · HENSLEY, AR · NPI 1588613327
Verified facts
What the public records show
CMS Open Payments records show Robert E Walton, D.O. received $119.06 in general payments during 2025 across 6 reported records.
GlaxoSmithKline, LLC. accounted for 53.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $63.39 | 53.2% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29.21 | 24.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $26.46 | 22.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $119.06 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $63.39 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $29.21 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $26.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 152 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
152 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 506 | 92 |
| Gabapentin | Gabapentin | 343 | 66 |
| Amlodipine Besylate | Amlodipine Besylate | 334 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 296 | 72 |
| Omeprazole | Omeprazole | 276 | 56 |
| Metformin Hcl | Metformin Hcl | 235 | 58 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 210 | 65 |
| Atorvastatin Calcium | Atorvastatin Calcium | 210 | 51 |
| Lisinopril | Lisinopril | 203 | 59 |
| Sertraline Hcl | Sertraline Hcl | 185 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 184 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 172 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 166 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 164 | 32 |
| Losartan Potassium | Losartan Potassium | 157 | 35 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 152 | 27 |
| Tramadol Hcl | Tramadol Hcl | 140 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 140 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 134 | 74 |
| Azithromycin | Azithromycin | 130 | 77 |
| Meloxicam | Meloxicam | 128 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 113 | 24 |
| Clonazepam | Clonazepam | 111 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 105 | 24 |
| Methylprednisolone | Methylprednisolone | 94 | 62 |
| Glimepiride | Glimepiride | 79 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 78 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 75 | 17 |
| Furosemide | Furosemide | 70 | 20 |
| Simvastatin | Simvastatin | 70 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 16 |
| Allopurinol | Allopurinol | 66 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 19 |
| Lorazepam | Lorazepam | 65 | 11 |
| Potassium Chloride | Potassium Chloride | 63 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 63 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 60 | suppressed |
| Cefdinir | Cefdinir | 59 | 50 |
| Tradjenta | Linagliptin | 59 | 12 |
| Ozempic | Semaglutide | 58 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 57 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 54 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 52 | 21 |
| Eliquis | Apixaban | 51 | suppressed |
| Atenolol | Atenolol | 50 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 50 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 47 | 38 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 46 | suppressed |
| Prednisone | Prednisone | 46 | 18 |
| Alprazolam | Alprazolam | 45 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 45 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 43 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | suppressed |
| Mupirocin | Mupirocin | 41 | 29 |
| Famotidine | Famotidine | 40 | suppressed |
| Colchicine | Colchicine | 39 | suppressed |
| Primidone | Primidone | 39 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 14 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 36 | suppressed |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | 11 |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 22 |
| Propranolol Hcl Er | Propranolol Hcl | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Dutasteride | Dutasteride | 29 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 18 |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Febuxostat | Febuxostat | 22 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 21 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 21 | suppressed |
| Ssd | Silver Sulfadiazine | 21 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Carvedilol | Carvedilol | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Cefadroxil | Cefadroxil | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $119.06 · 6 records | GlaxoSmithKline, LLC. | AIRSUPRA, TRELEGY ELLIPTA, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error